Horizon Discovery Group (LSE: HZD), a UK-based biotech specializing in gene editing, announced the launch of a new platform for immuno-oncology on Friday.
The platform consists of several high-throughput assays which are expected to enable researchers to test thousands of potential anti-cancer drugs that recruit the body’s own immune system to fight the disease.
Researchers will be able to study how new drugs are able to activate different types of immune cells as well as increase their ability to kill tumors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze